West Pharmaceutical Services Gestione

Gestione criteri di controllo 3/4

West Pharmaceutical Services Il CEO è Eric Green, nominato in Apr2015, e ha un mandato di 9.58 anni. la retribuzione annua totale è $ 9.40M, composta da 12.1% di stipendio e 87.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.23% delle azioni della società, per un valore di € 47.71M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 9.5 anni.

Informazioni chiave

Eric Green

Amministratore delegato

US$9.4m

Compenso totale

Percentuale dello stipendio del CEO	12.1%
Mandato del CEO	9.6yrs
Proprietà del CEO	0.2%
Durata media del management	4.5yrs
Durata media del Consiglio di amministrazione	9.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Eric Green rispetto agli utili di West Pharmaceutical Services?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$500m
Jun 30 2024	n/a	n/a	US$525m
Mar 31 2024	n/a	n/a	US$569m
Dec 31 2023	US$9m	US$1m	US$593m
Sep 30 2023	n/a	n/a	US$559m
Jun 30 2023	n/a	n/a	US$519m
Mar 31 2023	n/a	n/a	US$552m
Dec 31 2022	US$8m	US$1m	US$586m
Sep 30 2022	n/a	n/a	US$631m
Jun 30 2022	n/a	n/a	US$686m
Mar 31 2022	n/a	n/a	US$684m
Dec 31 2021	US$9m	US$1m	US$662m
Sep 30 2021	n/a	n/a	US$613m
Jun 30 2021	n/a	n/a	US$519m
Mar 31 2021	n/a	n/a	US$423m
Dec 31 2020	US$8m	US$989k	US$346m
Sep 30 2020	n/a	n/a	US$312m
Jun 30 2020	n/a	n/a	US$286m
Mar 31 2020	n/a	n/a	US$261m
Dec 31 2019	US$7m	US$936k	US$242m
Sep 30 2019	n/a	n/a	US$230m
Jun 30 2019	n/a	n/a	US$229m
Mar 31 2019	n/a	n/a	US$219m
Dec 31 2018	US$5m	US$880k	US$207m
Sep 30 2018	n/a	n/a	US$155m
Jun 30 2018	n/a	n/a	US$151m
Mar 31 2018	n/a	n/a	US$133m
Dec 31 2017	US$5m	US$824k	US$151m

Compensazione vs Mercato: La retribuzione totale di Eric ($USD 9.40M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.20M ).

Compensazione vs guadagni: La retribuzione di Eric è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Eric Green (54 yo)

9.6yrs

Mandato

US$9,395,896

Compensazione

Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric Green	Non-Independent Chair of the Board	9.6yrs	US$9.40m	0.23% € 47.7m
Bernard Birkett	Senior VP & CFO	6.4yrs	US$3.64m	0.0095% € 2.0m
Silji Abraham	Senior VP & CTO	3.9yrs	US$1.67m	0.0040% € 812.9k
Kimberly MacKay	Senior VP	3.9yrs	US$1.49m	0.0019% € 386.9k
Cindy Reiss-Clark	Senior VP & Chief Commercial Officer	5yrs	US$1.53m	0.0067% € 1.4m
Chad Winters	VP, Chief Accounting Officer & Corporate Controller	5.1yrs	Nessun dato	0.0018% € 372.5k
John Sweeney	Head of Investor Relations	no data	Nessun dato	Nessun dato
Michele Polinsky	Vice President of Global Communications	no data	Nessun dato	Nessun dato
Rudy Poussot	Senior VP of Strategy & Corporate Development	less than a year	Nessun dato	Nessun dato
Annette Favorite	Chief Human Resources Officer & Senior VP	9.1yrs	US$1.14m	0.0090% € 1.8m
Kathy DePadua	Senior VP and Chief Quality & Regulatory Officer	2.5yrs	Nessun dato	Nessun dato
Aileen Ruff-Patry	President of Contract Manufacturing	less than a year	Nessun dato	Nessun dato

4.5yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di WPS è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric Green	Non-Independent Chair of the Board	9.5yrs	US$9.40m	0.23% € 47.7m
Myla Lai-Goldman	Independent Director	10.8yrs	US$359.35k	0.024% € 4.9m
Robert Friel	Independent Director	4.8yrs	US$330.66k	0.0034% € 691.5k
Thomas Hofmann	Independent Director	17.1yrs	US$390.35k	0.059% € 12.2m
Mark Buthman	Independent Director	13.8yrs	US$378.23k	0.056% € 11.5m
Douglas Michels	Independent Director	13.8yrs	US$377.01k	0.059% € 12.2m
Paolo Pucci	Lead Independent Director	8.2yrs	US$367.44k	0.012% € 2.5m
Stephen Lockhart	Independent Director	2.3yrs	US$331.46k	0.0015% € 304.6k
William Feehery	Independent Director	12.8yrs	US$362.83k	0.040% € 8.3m
Deborah L. Keller	Independent Director	7.4yrs	US$333.45k	Nessun dato
Morihiro Sudo	Honorary Director	no data	Nessun dato	Nessun dato
Molly Joseph	Independent Director	3.3yrs	US$321.43k	0.00087% € 179.0k

9.5yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di WPS sono considerati esperti (durata media dell'incarico 9.5 anni).

West Pharmaceutical Services Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

West Pharmaceutical Services, Inc. Announces Resignation of Silji Abraham as Senior Vice President & Chief Technology Officer, Effective December 31, 2024

Insufficient new directors

Bernard Birkett No Longer Have Principal Operating Officer Position of West Pharmaceutical Services, Inc

West Pharmaceutical Services, Inc., Annual General Meeting, Apr 23, 2024

Independent Director recently sold €404k worth of stock

Key Executive recently sold €4.7m worth of stock

Recent updates

Third quarter dividend of US$0.21 announced

Third quarter 2024 earnings released: EPS: US$1.87 (vs US$2.17 in 3Q 2023)

West Pharmaceutical Services, Inc. Raises Earnings Guidance for the Full Year 2024

West Pharmaceutical Services, Inc. to Report Q3, 2024 Results on Oct 24, 2024

West Pharmaceutical Services, Inc. Announces Resignation of Silji Abraham as Senior Vice President & Chief Technology Officer, Effective December 31, 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$1.53 (vs US$2.09 in 2Q 2023)

Upcoming dividend of US$0.20 per share

West Pharmaceutical Services, Inc. to Report Q2, 2024 Results on Jul 25, 2024

West Pharmaceutical Services, Inc. Introduces Daikyo Crystal Zenith® Ready-to-Use Nested Vials in Tub at the International Society for Cell and Gene Therapy

Dividend of US$0.20 announced

Bernard Birkett No Longer Have Principal Operating Officer Position of West Pharmaceutical Services, Inc

West Pharmaceutical Services, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$1.57 (vs US$1.88 in 1Q 2023)

Upcoming dividend of US$0.20 per share

West Pharmaceutical Services, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

West Pharmaceutical Services, Inc., Annual General Meeting, Apr 23, 2024

Fourth quarter dividend of US$0.20 announced

West Pharmaceutical Services, Inc. Announces Second Quarter 2024 Dividend, Payable on May 1, 2024

Full year 2023 earnings released: EPS: US$7.99 (vs US$7.88 in FY 2022)

Investor sentiment deteriorates as stock falls 18%

West Pharmaceutical Services, Inc. Provides Earnings Guidance for the Full Year 2024

West Pharmaceutical Services, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Upcoming dividend of US$0.20 per share at 0.2% yield

West Pharmaceutical Services, Inc. Announces Dividend for the First Quarter of 2024, Payable on February 7, 2024

West Pharmaceutical Services, Inc. Receives FDA 510(K) Clearance for Vial2bag Advanced 13mm Admixture Device

Upcoming dividend of US$0.20 per share at 0.3% yield

West Pharmaceutical Services, Inc. Approves Fourth-Quarter 2023 Dividend, Payable on November 15, 2023

Third quarter 2023 earnings released: EPS: US$2.17 (vs US$1.62 in 3Q 2022)

West Pharmaceutical Services, Inc. to Report Q3, 2023 Results on Oct 26, 2023

West Pharmaceutical Services, Inc. Revises Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings released: EPS: US$2.09 (vs US$2.53 in 2Q 2022)

Upcoming dividend of US$0.19 per share at 0.2% yield

West Pharmaceutical Services, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Independent Director recently sold €404k worth of stock

First quarter 2023 earnings released: EPS: US$1.88 (vs US$2.34 in 1Q 2022)

Upcoming dividend of US$0.19 per share at 0.2% yield

Full year 2022 earnings released: EPS: US$7.88 (vs US$8.90 in FY 2021)

West Pharmaceutical Services, Inc. (NYSE:WST) announces an Equity Buyback for $1,000 million worth of its shares.

West Pharmaceutical Services, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Upcoming dividend of US$0.19 per share

West Pharmaceutical Services, Inc. Approves First-Quarter 2023 Dividend, Payable on February 1, 2023

Upcoming dividend of US$0.19 per share

Third quarter 2022 earnings released: EPS: US$1.62 (vs US$2.37 in 3Q 2021)

West Pharmaceutical Services, Inc. Updating Full-Year 2022 Guidance

West Pharmaceutical Services, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Key Executive recently sold €4.7m worth of stock

Second quarter 2022 earnings released: EPS: US$2.53 (vs US$2.53 in 2Q 2021)

West Pharmaceutical Services, Inc. Provides Earnings Guidance for the Full Year 2022

West Pharmaceutical Services, Inc. Elects Stephen Lockhart as New Director to the Board

West Pharmaceutical Services, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Upcoming dividend of US$0.18 per share

West Pharmaceutical Services, Inc. Introduces Daikyo Crystal Zenith 2.25mL Insert Needle Syringe System At BIO International Convention

West Pharmaceutical Services, Inc. Announces Executive Leadership Appointments

First quarter 2022 earnings released: EPS: US$2.34 (vs US$2.05 in 1Q 2021)

West Pharmaceutical Services, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Upcoming dividend of US$0.18 per share

West Pharmaceutical Services, Inc. Announces Board Changes

West Pharmaceutical Services, Inc. Announces Second-Quarter 2022 Dividend, Payable on May 4, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

West Pharmaceutical Services, Inc. Announces Asset Impairment for the Fourth Quarter Ended December 31, 2021

West Pharmaceutical Services, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Upcoming dividend of US$0.18 per share

Upcoming dividend of US$0.18 per share

Second quarter 2021 earnings released: EPS US$2.53 (vs US$1.24 in 2Q 2020)

Upcoming dividend of US$0.17 per share

Senior VP & Chief Technology Officer recently sold €598k worth of stock